Insulin prices and pharmacy benefit manager rebates: pin the tail on the patient

by Duane Schulthess

Available online 19 March 2020

What’s the impact of Pharmaceutical Benefit Managers on US Insulin prices? In researching HR3, Vital Transformation found $2 bil in ‘lost’ revenue reported in Medicare Part D, but missing in audited actual sales on company balance sheets. Time to bring back the Rebate Rule?